EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 醫脈通科技有限公司 | | 股份代號 | 02192 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度的末期股息 | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.1435 RMB | | 股東批准日期 | 2026年5月15日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.1629 HKD | | 匯率 | 1 ...

Financial Performance - Revenue for the year ended December 31, 2025, reached RMB 642,155,000, representing a 15.0% increase from RMB 558,455,000 in 2024[2] - Gross profit for the same period was RMB 385,440,000, up 17.8% from RMB 327,222,000 in 2024[2] - The adjusted net profit for the year was RMB 342,114,000, reflecting a 5.7% increase from RMB 323,600,000 in 2024[2] - Net profit rose from RMB 330.3 million for the year ending December 31, 2024, to RMB 347.9 million for 2025, maintaining a net profit margin of 54.2%[10] - The group's revenue increased by approximately 15.0% from RMB 558.5 million for the year ending December 31, 2024, to approximately RMB 642.2 million for the year ending December 31, 2025, primarily driven by growth in precision marketing and enterprise solutions[27] - The group's operating profit before tax increased by approximately 5.8% from RMB 340.5 million for the year ending December 31, 2024, to approximately RMB 360.3 million for the year ending December 31, 2025[38] - The group reported a total comprehensive income of RMB 259.730 million for the year, down from RMB 387.933 million in 2024[59] Client Engagement and User Growth - The number of medical clients for precision marketing and enterprise solutions increased to 269, compared to 228 in 2024, reflecting a growth in client engagement[4] - Average monthly active users reached 3.02 million, an increase from 2.65 million in 2024, indicating enhanced user engagement on the platform[4] - The number of clients for the precision marketing and enterprise solutions increased by 18.0% to 269 in 2025, compared to 228 in 2024[12] - Paid click-throughs increased from 13.3 million in 2024 to 15.7 million in 2025, reflecting enhanced engagement[12] - The patient management platform accumulated approximately 634,000 users and 178,000 participating physicians by the end of 2025[21] Product and Service Development - The company has developed a medical large model focusing on clinical decision-making, which has been recognized for its algorithm safety and compliance by national authorities[7] - The company launched AI-driven products such as MedSeeker, MedPaper, and MedAssister to enhance clinical decision-making and academic research efficiency[8] - The company is expanding its clinical research service capabilities, focusing on areas such as oncology, hematology, neurology, pediatrics, and cardiovascular diseases[15] - The case library launched in April 2025 has published over 5,700 cases, enhancing clinical decision-making for physicians[17] - The clinical guidelines on the platform have increased to 35,000 articles, with over 4,000 new guidelines added, improving search functionality through AI integration[17] Revenue Breakdown - Revenue from precision marketing and enterprise solutions accounted for 92.6% of total revenue, amounting to RMB 594,485,000, a 16.0% increase from the previous year[3] - Revenue from the precision marketing and enterprise solutions reached RMB 594.5 million in 2025, a 16.0% increase from RMB 512.5 million in 2024[12] - Revenue from medical knowledge solutions grew by 6.0% to RMB 19.0 million in 2025, up from RMB 17.9 million in 2024[16] - Revenue from intelligent patient management solutions was RMB 28,707 thousand in 2025, slightly up from RMB 28,040 thousand in 2024[73] Financial Position and Investments - As of December 31, 2025, the group had cash and cash equivalents of approximately RMB 2,567.1 million, down from RMB 3,844.7 million as of December 31, 2024[47] - The group held debt investments totaling RMB 1,807.0 million as of December 31, 2025, with expected annual returns ranging from 3.20% to 5.50%[48] - Capital expenditures for the year ended December 31, 2025, were approximately RMB 24.5 million, compared to RMB 19.0 million for the year ended December 31, 2024[53] - The company plans to continue strategic investments and acquisitions that align with its existing solutions to expand its customer base and enhance technical capabilities[55] - The company plans to utilize approximately RMB 280.7 million for improving medical knowledge solutions by December 2027[103] Governance and Compliance - The company has established an audit committee consisting of three independent non-executive directors to ensure compliance with applicable accounting principles and regulations[109] - The company has adhered to the corporate governance code, with a noted deviation regarding the roles of the Chairman and CEO being held by the same individual[106] - The company has confirmed that all directors complied with the standard code of conduct for securities trading during the reporting year[107] Employee and Operational Costs - The total employee cost for the year was approximately RMB 209.0 million, up from RMB 190.8 million in 2024, primarily due to an increase in sales and AI research personnel[56] - The company's employee benefits expenses totaled RMB 201,234,000 in 2025, up from RMB 181,581,000 in 2024, representing an increase of about 10.8%[82] - Research and development expenses increased to RMB 76,530,000 in 2025 from RMB 64,581,000 in 2024, reflecting a growth of about 18.5%[82] Shareholder Information - The company proposed a final dividend of RMB 14.35 per share for 2025, up from RMB 13.66 per share in 2024, which is an increase of approximately 5.0%[86] - The company has issued 737,030,875 shares as of December 31, 2025, up from 732,876,000 shares in 2024[95] - The proposed final dividend is RMB 0.1435 per share, equivalent to HKD 0.1629 per share, pending shareholder approval[100]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The era of AI in healthcare is approaching, and learning from overseas development models is necessary [5] - AI products in healthcare face obstacles in data exchange, regulatory clarity, and payment systems, with the U.S. leading in data sharing and regulatory frameworks [6] - Investment opportunities in AI healthcare are centered around data resources, platforms, and clear C-end application scenarios [6] Summary by Sections Introduction - The rapid development of large model technologies, represented by Transformers, significantly impacts the healthcare industry, showing disruptive potential across various stakeholders [15] Overseas AI Healthcare Ecosystem Progress - The U.S. has established a smooth data exchange system and a regulatory framework for AI products, with a cautious approach to including AI products in insurance payment systems [6][27] - The report highlights the need for studying overseas data sharing mechanisms and regulatory policies to inform domestic AI healthcare companies [27] Investment Insights and Recommendations - Key investment lines include data asset foundations, data resource platforms, and C-end application companies with clear scenarios [6] - Notable companies to watch include: - Data asset foundations: Chuangshihui Kang, Weining Health, Wanda Information, Jiahe Meikang - Data resource platforms: Meinian Health, Jinyu Medical, Dian Diagnosis - C-end application companies: Yimaitong, Alibaba Health, JD Health [6] Regulatory and Payment Frameworks - The report discusses the evolving regulatory landscape for AI products, emphasizing the need for adaptive regulations that ensure patient safety while encouraging innovation [46] - In the U.S., over 1,400 AI products have received FDA approval, but only a few have been included in insurance reimbursement frameworks [48] - The report notes that domestic payment policies for AI products are still in exploration, with a focus on imaging products [55]

Group 1 - The company, 医脉通 (02192.HK), announced that it will hold a board meeting on March 26, 2026, to consider and approve the annual performance for the year ending December 31, 2025, along with its release [1] - The board will also consider the distribution of a final dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 董事會會議日期 醫脈通科技有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司 將於二零二六年三月二十六日（星期四）舉行董事會會議，藉以考慮及批准本 公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其發佈， 並考慮派發末期股息（如有）。 承董事會命 醫脈通科技有限公司 董事長及首席執行官 田立平 Medlive Technology Co., Ltd. 香港，二零二六年三月十六日 醫脈通科技有限公司 於本公告日期，董事會包括執行董事田立平女士、田立新先生、田立軍先生及周欣女士；非 執行董事槌屋英二先生及金色一賢先生；以及獨立非執行董事葉霖先生、馬軍醫師及王珊女士。 ...

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of ordinary shares to a director and an employee as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 300,000 ordinary shares to a director exercising share options on March 4, 2026 [1] - The company will issue 25,000 ordinary shares to an employee exercising share options on March 4, 2026 [1]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of ordinary shares as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 300,000 ordinary shares to a director exercising share options on March 4, 2026 [1] - The company will also issue 25,000 ordinary shares to an employee exercising share options on the same date [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2026年3月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 02192 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已 ...

Core Viewpoint - FIL Limited has increased its stake in 医脉通 (Medlink) from 4.67% to 5.04% by purchasing 2.7155 million shares at an average price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [1][2]. Group 1 - FIL Limited acquired 2.7155 million shares of 医脉通 on February 24, 2026, at an average price of HKD 9.6301 per share [1][2]. - Following the acquisition, FIL Limited's total shareholding in 医脉通 increased to 37.1726 million shares [1][2]. - The ownership percentage of FIL Limited rose from 4.67% to 5.04% after the transaction [1][2].

Group 1 - FIL Limited increased its stake in Yimaitong (02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [2][5] - After the acquisition, FIL Limited's total shareholding in Yimaitong reached approximately 37.1726 million shares, representing a new ownership percentage of 5.04% [2][5]